Onderneming PHAXIAM Therapeutics S.A. Nasdaq
Aandelen
ERYP
US29604W2070
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 68
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 23-06-23 |
Karine Charton
PRN | Corporate Officer/Principal | - | 23-06-23 |
General Counsel | - | 23-06-23 | |
Human Resources Officer | - | 23-06-23 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 23-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 23-06-23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-23 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-23 |
Martine George
BRD | Director/Board Member | 76 | 23-06-23 |
Director/Board Member | 66 | 23-06-23 | |
Didier Hoch
CHM | Chairman | 68 | 23-06-23 |
Leila Nicolas
BRD | Director/Board Member | - | 23-06-23 |
Robert Sebbag
BRD | Director/Board Member | 73 | 23-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 6 075 105 | 5 597 574 ( 92,14 %) | 250 ( 0,004115 %) | 92,14 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
250 | 0.00% | 805 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |